EXSCIENTIA
Exscientia , an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron） , a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved , Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI . LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cardano Summit 2025 Concludes In Berlin: Trust Emerges As The Winner with Traditional Financial Firms Feeling Blockchain FOMO17.11.2025 14:23:00 CET | Press release
Cardano Foundation Highlights Ambitious Growth Roadmap and Announces Singapore for 2026 Event Last week’s Cardano Summit 2025 at Berlin’s iconic Gasometer heard from 140 speakers, brought together close to 800 attendees from over 70 countries, and attracted over 25,000 online participants, showcasing significant momentum in enterprise blockchain adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117496852/en/ Cardano Foundation CEO Frederik Gregaard on the main stage at the Cardano Summit 2025 in Berlin Across two days of strategic discussions, enterprise leaders joined the Cardano community to discuss industry readiness, DeFi expansion, and the convergence of AI with distributed systems. The Cardano Foundation also outlined its 2026 roadmap highlighting decentralized finance (DeFi) liquidity, Web3 integration, and real-world asset (RWA) tokenization as key focus areas. Additionally, Singapore was unveiled as the lo
MUSASHI JAPAN by TAIMATSU Launches “Dual Blades” – A Black Friday Experience Redefining Luxury Craftsmanship17.11.2025 14:11:00 CET | Press release
MUSASHI JAPAN by TAIMATSU, a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, announces its 2025 Black Friday campaign: “Dual Blades.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117626760/en/ This year, MUSASHI moves beyond traditional discount culture to celebrate the philosophy of balance, precision, and mastery. Inspired by the concept of Nitōryu — the dual-blade technique symbolizing harmony between strength and grace — the campaign invites customers to experience the unity and balance of two blades. What begins as a Black Friday promotion becomes an artistic expression of Japanese craftsmanship. At Musashi Japan, we extend the history and philosophy of Nitōryu into the modern kitchen, guiding customers toward the ideal combination of knives for their everyday cooking. Not everything can—or should—be cut with a single knife. Each ingredient deserves the blade designed f
Riskified Champions Fraud Prevention as a Leading Partner of International Fraud Awareness Week 202517.11.2025 14:00:00 CET | Press release
During the critical holiday shopping season, Riskified calls for greater ecommerce safety to maintain consumer trust Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, announces its participation in International Fraud Awareness Week, taking place November 16–22, 2025. Joining hundreds of organizations worldwide, Riskified aims to raise awareness about the urgent need to fight fraud and help safeguard merchants and their customers globally, especially as online shopping heats up ahead of the holidays. Deloitte forecasts holiday ecommerce sales of $305–$311 billion in 2025, bringing a wave of new and returning customers and incremental revenue to businesses. Unfortunately, this growth also presents fraudsters with an enticing opportunity: losses from ecommerce fraud are projected to reach $107 billion by 2029, according to Juniper Research. AI is reshaping both shopping behavior and criminal tactics at unprecedented speed. Riskified data shows t
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom